DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD

Information source: Pulmagen Therapeutics
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Obstructive Pulmonary Disease

Intervention: Theophylline - ADC4022 (Drug); Placebo (Drug); Budesonide (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Pulmagen Therapeutics

Official(s) and/or principal investigator(s):
Neil Barnes, MD PhD, Principal Investigator, Affiliation: London Chest Hospital

Summary

The purpose of this study is to assess the tolerability and efficacy of inhaled theophylline (ADC4022) on markers of pulmonary inflammation (white blood cells) in induced sputum and in bronchial biopsy samples in subjects with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) when co-administered with budesonide and compared to placebo.

Clinical Details

Official title: A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 on Markers of Pulmonary Inflammation in Subjects With Moderate to Severe COPD

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Pulmonary inflammation: Cell counts (neutrophils, macrophages, eosinophils and lymphocytes) in induced sputum samples

Secondary outcome:

Pulmonary inflammation: Cytokine IL-8 concentration in induced sputum

Pulmonary inflammation: CD8+ and CD68+ from bronchial biopsy

Tolerability to ADC4022

Eligibility

Minimum age: 40 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Confirmed diagnosis of COPD that has been symptomatic for at least 2 years

- The subject has moderate to severe COPD, as defined by the American Thoracic Society

and the European Respiratory Society

- The subject can produce an adequate sputum specimen after induction

- The subject has a history of ≥ 10-pack years of cigarette smoking

- The subject has either a ≤15% increase or ≤200 ml increase in FEV1 from pre-dose

following a fixed dose of bronchodilator therapy

- The subject is able to provide written, informed consent to participate

Exclusion Criteria:

- The subject has experienced a respiratory tract infection and/or an exacerbation of

COPD within 30 days

- The subject uses systemic corticosteroids (oral or parenteral)

- The subject has received long term oxygen therapy within 30 days

- The subject has a previous history or diagnosis of asthma

- The subject has a chest x-ray within the past 12 months which is diagnostic of an

active or clinically significant disease other than COPD

- The subject has a history or presence of active tuberculosis, cystic fibrosis,

bronchiectasis, lung cancer or sarcoidosis or any other clinically important lung diseases

- The subject has had radiation or chemotherapy within the previous 12 months

- The subject has a history of anaphylaxis associated with medicinal products

- The subject is pregnant, intends to become pregnant, or is breast feeding

- The subject's alcohol intake is excessive.

- The subject participated in another study (for a marketed drug) within 3 months

before the start of this study or (for an investigational drug) within 4 months before the start of this study. Other inclusion/exclusion criteria may also apply

Locations and Contacts

Silisian Medical University, Katowice-Ligota 40-752, Poland

Jagiellonian University of Medicine, Krakow 31-066, Poland

Medical University in Lodz, Lodz 90-153, Poland

National Tuberculosis and Lung Diseases Research Institute, Warsaw 01-138, Poland

Warsaw University Medical School, Warsaw 02-097, Poland

The London Chest Hospital, London E2 9JX, United Kingdom

Medicines Evaluation Unit, Manchester M23 9QZ, United Kingdom

Glenfield Hospital, Leicester, Leicestershire LE3 9QP, United Kingdom

Additional Information

Starting date: February 2008
Last updated: February 27, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017